

# 1 **Revealing the biology behind MRI signatures in high grade** 2 **glioma**

3 Erika M Lewis <sup>1</sup>, Lingchao Mao <sup>2</sup>, Lujia Wang <sup>2</sup>, Kristin R Swanson <sup>3,4</sup>, Ramon F Barajas <sup>5,6,7</sup>,  
4 Jing Li <sup>2</sup>, Nhan L Tran <sup>4,8</sup>, Leland S Hu <sup>3,9,10\*</sup>, Christopher L Plaisier <sup>1\*</sup>

5  
6 <sup>1</sup> School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ,  
7 85287, USA.

8 <sup>2</sup> H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of  
9 Technology, Atlanta, GA, 30332, USA.

10 <sup>3</sup> Mathematical Neuro-Oncology Lab, Department of Neurological Surgery, Mayo Clinic,  
11 Phoenix, AZ, 85054, USA.

12 <sup>4</sup> Department of Neurosurgery, Mayo Clinic, Phoenix, AZ, 85054, USA.

13 <sup>5</sup> Advanced Imaging Research Center, Oregon Health & Sciences University, USA.

14 <sup>6</sup> Department of Radiology, Neuroradiology Section, Oregon Health & Sciences University, USA.

15 <sup>7</sup> Knight Cancer Institute, Oregon Health & Sciences University, USA.

16 <sup>8</sup> Department of Cancer Biology, Mayo Clinic, Phoenix, AZ, 85054, USA.

17 <sup>9</sup> Department of Radiology, Mayo Clinic, Phoenix, AZ, 85054, USA.

18 <sup>10</sup> School of Computing, Informatics, and Decision Systems Engineering, Arizona State  
19 University, Tempe, AZ, 85281, USA.

20

21 \*To whom correspondence should be addressed: [Hu.Leland@mayo.edu](mailto:Hu.Leland@mayo.edu) (L.S.H.) and  
22 [plaisier@asu.edu](mailto:plaisier@asu.edu) (C.L.P.)

## 23 **Abstract**

24 Magnetic resonance imaging (MRI) measurements are routinely collected during the treatment  
25 of high-grade gliomas (HGGs) to characterize tumor boundaries and guide surgical tumor  
26 resection. Using spatially matched MRI and transcriptomics we discovered HGG tumor biology  
27 captured by MRI measurements. We strategically overlaid the spatially matched omics  
28 characterizations onto a pre-existing transcriptional map of glioblastoma multiforme (GBM) to  
29 enhance the robustness of our analyses. We discovered that T1+C measurements, designed to  
30 capture vasculature and blood brain barrier (BBB) breakdown and subsequent contrast  
31 extravasation, also indirectly reveal immune cell infiltration. The disruption of the vasculature  
32 and BBB within the tumor creates a permissive infiltrative environment that enables the  
33 transmigration of anti-inflammatory macrophages into tumors. These relationships were  
34 validated through histology and enrichment of genes associated with immune cell transmigration  
35 and proliferation. Additionally, T2-weighted (T2W) and mean diffusivity (MD) measurements  
36 were associated with angiogenesis and validated using histology and enrichment of genes  
37 involved in neovascularization. Furthermore, we establish an unbiased approach for identifying  
38 additional linkages between MRI measurements and tumor biology in future studies, particularly  
39 with the integration of novel MRI techniques. Lastly, we illustrated how noninvasive MRI can be  
40 used to map HGG biology spatially across a tumor, and this provides a platform to develop  
41 diagnostics, prognostics, or treatment efficacy biomarkers to improve patient outcomes.

42  
43 **Keywords:** MRI, tumor biology, immune infiltration, angiogenesis, image localized biopsies

## 44 Introduction

45 Conventional magnetic resonance imaging (MRI) is a cornerstone for noninvasively diagnosing  
46 and devising treatment strategies for deadly high-grade glioma (HGG) tumors. Currently, MRI is  
47 primarily used to establish tumor boundaries that are readily observed as regions where the  
48 blood-brain-barrier (BBB) has been disrupted allowing for MRI contrast extravasation into the  
49 tumor interstitial space (1). Accurately delineating tumor boundaries is crucial for determining  
50 tumor burden, which translates clinically to the extent of surgical resection (2). The ubiquitous  
51 use of MRI in the clinical management of HGG tumors, coupled with the development of new  
52 MRI techniques, demands further study to elucidate the biological phenomena captured by  
53 imaging HGG tumors.

54 MRI measurements from HGG tumors have also been linked to tumor heterogeneity (3, 4),  
55 tumor percentage (5), cellular density (6, 7), and found to be predictive in prognostic and  
56 recurrence models (8–10). Simultaneous imaging and molecular characterization provide a  
57 platform for linking noninvasive biophysical imaging patterns to their molecular underpinnings.  
58 Examples include associations with EGFR mutational status (11) and CD49 immune cell  
59 presence (12) onto three-dimensional representations of a tumor. We hypothesize that  
60 additional insights into tumor biology can be extracted from MRI through integration of imaging  
61 and molecular measurements.

62 We conducted a system level integrative study to reveal the clinically relevant aspects of HGG  
63 tumor biology that can be captured through noninvasive MRI measurements. Establishing  
64 connections between MRI measurements and HGG tumor biology requires a spatially matched  
65 quantification of MRI alongside omics-scale molecular characterization. We generated a cohort  
66 of spatially matched MRI and transcriptomics characterized contrast enhancing (CE) HGG  
67 tumors (13). In the spatially matched cohort, we collected MRI measurements for T1-weighted  
68 contrast-enhanced (T1+C), T2-weighted (T2W), and two diffusion weighted imaging metrics:  
69 fractional anisotropy (FA), and mean diffusivity (MD). T1+C utilizes a contrast agent to identify  
70 areas of BBB disruption by registering where the contrast agent leaks out of vasculature into the  
71 surrounding tissue interstitia (14). T1+C is generally used as a surrogate for tumor presence  
72 and to define HGG tumor burden (14). T2W captures tissue water content with bright areas  
73 extending past the T1+C signal indicating vasogenic edema (14). An infiltrative tumor can  
74 extend into these regions of edema, and T2W is thus valuable alongside T1+C in guiding the  
75 extent of surgical resection (14). T1+C and T2W are commonly used to facilitate many aspects  
76 of HGG patient care, including initial diagnosis, treatment planning, and response assessment  
77 after first-line therapy. Advanced diffusion-based MRI techniques, such as FA and MD, have  
78 gained traction as essential complementary techniques in neuro-oncology. FA is a form of  
79 diffusion tensor imaging (DTI) that measures directionally dependent water diffusion (14). FA  
80 values measure perturbation from linear diffusion which is often used to characterize the risk for  
81 tumor infiltration of white matter tracts during pre-surgical mapping (15). MD is a form of  
82 diffusion-weighted imaging (DWI) that measures extracellular bulk water diffusion (14). MD has  
83 classically been used to measure water restriction related to cytotoxic edema and has been  
84 correlated with constrained diffusion due to cellular packing in neuro-oncology (16). Together,  
85 these MRI measurements quantify a wide range of biophysical phenomena that could potentially  
86 be used as noninvasive proxies for the underlying biology of HGG tumors.

87 Collecting spatially matched biopsies and MRI measurements from a tumor is a complex  
88 surgical undertaking, which leads to smaller cohort sizes. In this study, we boosted the signal in  
89 our analyses by overlaying the omics characterizations onto a previously constructed  
90 transcriptional map of glioblastoma multiforme (GBM). The gbmSYGNAL network was  
91 constructed using multi-omic profiles of 422 patient tumors from The Cancer Genome Atlas  
92 (TCGA) (17). The 5,194 genes in the gbmSYGNAL network are aggregated into 500 co-  
93 regulated gene expression signatures (biclusters). Biclusters contain genes that were linked to  
94 pathways and biological processes through functional enrichment analysis. We then linked  
95 enriched pathways and biological processes to the hallmarks of cancer (17–20). The hallmarks  
96 of cancer describe clinically relevant oncogenic functions acquired by all cancer types and are  
97 especially relevant to HGGs (21). We aim to identify MRI proxies for HGG tumor biology by  
98 discovering which spatially matched MRI measurements are predictive of clinically relevant  
99 tumor biology encapsulated within biclusters.

## 100 **Methods**

### 101 **Patient recruitment and surgical biopsies**

102 Patient recruitment took place at both Barrow Neurological Institute (BNI) and Mayo Clinic in  
103 Arizona (MCA) through IRB approved protocols at each institution. Informed consent was  
104 obtained prior to enrollment. Patients recruited for these studies underwent preoperative  
105 stereotactic MRI for surgical resection and had a histologically confirmed diagnosis of high-  
106 grade glioma (grade III or IV) and most of the patient tumors were IDH WT (25 IDH WT and 5  
107 IDH mutant) (13). Most of the patient tumors were primary tumors (n = 23) and a smaller subset  
108 were recurrent tumors (n = 7). Characteristics of the patients, tumors and biopsies can be found  
109 in **Table S1**. The smallest possible diameter craniotomies were used to minimize brain shift. An  
110 average of 4-5 biopsies were collected from contrast-enhancing (CE) tumor regions separated  
111 by at least one cm using stereotactic surgical resection guided by conventional preoperative  
112 MRI (T1+C and T2W) (13). Biopsy locations were recorded via screen capture to allow co-  
113 registration of all MRI measurements.

### 114 **Conventional MRI to capture T1+C and T2W and general acquisition conditions**

115 Patients were imaged 24 hours before stereotactic surgery using a 3T MRI scanner (Sigma  
116 HDx; GE-Healthcare Waukesha Milwaukee; Ingenia, Philips Healthcare, Best, Netherlands;  
117 Magnetome Skyra; Siemens Healthcare, Erlangen Germany). Conventional MRI included  
118 standard pre- and post-contrast T1-weighted (T1, T1+C, respectively) and pre-contrast T2-  
119 weighted (T2W) sequences as previously described (13). Briefly, T1 and T1+C images were  
120 acquired using inversion-recover prepped (IR-prepped) spoiled gradient recalled-echo (SPGR)  
121 (T1/TR/TE = 300/6.8/2.8 ms; matrix = 320 x 224; FOV = 26 cm; thickness = 2 mm). The  
122 gadolinium based contrast agent (GBCA) was gadobenate dimeglumine for patients recruited at  
123 BNI and gadobutrol for patients recruited at MCA. T2W images were acquired using fast-spin-  
124 echo (FSE) (TR/TE = 5133/78 ms; matrix = 320 x 192; FOV = 26 cm; thickness = 2 mm).

### 125 **DTI was used to capture MD and FA**

126 DTI was performed using Spin-Echo Echo-planar imaging (EPI) [TR/TE 10,000/85.2 ms, matrix  
127 256 x 256; FOV 30 cm, 3 mm slice, 30 directions, ASSET, B = 0,1000]. The DTI DICOM files  
128 were converted into NifTI format using MRIConvert  
129 (<http://lcn.uoregon.edu/downloads/mriconvert>). DTI parametric maps were calculated using FSL  
130 (22) to generate whole-brain maps of MD and FA (13, 23).

### 131 **Image co-registration**

132 Each MRI measurement was co-registered to the DTI B0 anatomical image volume using tools  
133 from ITK (24) and IB Suite (Imaging Biometrics, LLC) (13). This approach to co-registration  
134 minimizes potential distortion errors from resampling that can adversely affect DTI metrics. The  
135 co-registered data was resampled to an in-plane voxel resolution of ~1.17 mm (256 x 256  
136 matrix) and a slice thickness of 3 mm.

### 137 **Region of interest (ROI) generation and image feature extraction**

138 The stereotactic location recorded for each biopsy during surgery defined a spatially matched  
139 MRI ROI measuring 8 x 8 x 1 voxels (9.6 x 9.6 x 3 mm). A board-certified neuroradiologist  
140 (L.S.H.) visually inspected all ROIs to ensure accuracy and that each biopsy specimen was in a

141 CE region of the tumor (13). Biopsies near potential artifacts (e.g., the floor of the anterior skull  
142 base, middle cranial fossa superior to the mastoid air cells, or craniectomy plate/screws) or in  
143 locations expected to yield no tissue (e.g., resection cavity or central necrosis) were excluded  
144 from the study. The mean value was calculated from the voxels in each biopsy's ROI for each  
145 MRI imaging technique, and these values were used for subsequent analyses linking MRI and  
146 transcriptomics.

#### 147 **RNA-sequencing of image-localized biopsies**

148 RNA was extracted from flash frozen tissue, libraries were constructed using the Illumina  
149 TruSeq v2 RNAseq kit, and paired-end reads were sequenced on an Illumina HiSeq 4000  
150 sequencer. FASTQ files were aligned to the human transcriptome (GRCh38.p37) using STAR,  
151 read counts were compiled using htseq-count, and batch effect was corrected using ComBat-  
152 seq as previously described (13). Tumor purity was computed for all 75 samples with whole  
153 exome sequencing (WES) as previously described (13).

#### 154 **Revising biclusters for use with RNA-seq data**

155 The first principal component corrected for sign (eigengenes) for each gbmSYGNAL bicluster  
156 was computed from the 75 CE MRI samples with RNA-seq, tumor purity, and MRI  
157 measurements (17, 25). Mixed effects models (MEMs) from the statsmodels package (26) were  
158 used to associate each bicluster eigengene with the expression of each constituent gene across  
159 the 75 samples, using patient ID, tumor purity and IDH mutational status as random effects, and  
160 patient ID was used to account for repeated samples collected from the same patient tumor.  
161 Genes with a positive beta value ( $\beta > 0$ ) and significant association ( $p\text{-value} \leq 0.05$ ) with the  
162 eigengene were included in the revised bicluster gene set definitions. Revised biclusters with at  
163 least five genes and an eigengene with a first principal component (PC1) variance explained  $\geq$   
164 0.3 were included in subsequent analyses.

#### 165 **Associating biclusters with MRI measurements**

166 Revised bicluster eigengenes were tested for association with MRI measurements across the  
167 75 samples using a MEM with patient ID, tumor purity, and IDH mutational status as random  
168 effects, and patient ID was used to account for repeated samples collected from the same  
169 patient tumor. Significant eigengene-MRI relationships were defined by a  $p\text{-value} \leq 0.05$ .

#### 170 **Linking MRI measurements to the hallmarks of cancer through gbmSYGNAL**

171 In the construction of gbmSYGNAL, biclusters were associated with GO biological process  
172 (GO:BP) terms and then linked to the hallmarks of cancer using semantic similarity (17).  
173 Significant linkage to the hallmarks of cancer was defined as a significant MRI association with  
174 the bicluster eigengene and a Jiang-Conrath semantic similarity score  $\geq 0.7$  to a hallmark of  
175 cancer. For each MRI measurement, hypergeometric enrichment analysis was used to test the  
176 significance of the overlap between MRI and hallmarks of cancer associated biclusters (17).  
177 Significant enrichment was defined by a BH-adjusted  $p\text{-value} \leq 0.05$  and an overlap  $> 0$ .

#### 178 **Linking MRI measurements to patient survival through gbmSYGNAL**

179 In constructing gbmSYGNAL, biclusters were linked to patient survival using Cox proportional  
180 hazards regression with patient age as a covariate and replicated in at least one of three  
181 independent validation cohorts used in Plaisier et al., 2016 (17). This study defined a significant

182 linkage between a bicluster and patient survival based on a  $p$ -value  $\leq 0.05$  and the hazard ratio  
183 in the same direction in all four cohorts (17). For each MRI measurement, hypergeometric  
184 enrichment analysis was used to test the significance of the enrichment between MRI and  
185 patient survival associated biclusters (17). Significant enrichment was defined by a BH-adjusted  
186  $p$ -value  $\leq 0.05$  and an overlap  $> 0$ .

### 187 **Clinical and molecular data for the TCGA GBM cohort**

188 The Pan-Cancer Atlas consortium contains standardized, normalized, batch-corrected, and  
189 platform-corrected multi-omics data for 11,080 participant tumors (27). This work used 422  
190 complete multi-omic GBM patient tumor profiles to validate findings from MRI data. The TCGA  
191 GBM cohort microarrays were used for RNA expression ( $n = 422$ ). TCGA aliquot barcodes  
192 flagged as "do not use" or excluded by pathology review from the Pan-Cancer Atlas Consortium  
193 were removed from the study. Overall survival (status and time to an event) for patients in the  
194 cohort were obtained from Liu et al. 2018 (28).

### 195 **Associating tumor infiltrating lymphocytes (TILs) to revised bicluster eigengenes in 196 TCGA**

197 Histologically determined quantification of TILs was available for 124 TCGA GBM tumors, where  
198 a value of 0 indicated TIL absence and values of 1 or 2 indicated TIL presence (29). For each  
199 revised bicluster eigengene, a t-test was performed comparing bicluster expression to TIL status  
200 (present vs. absent) across all 124 TCGA patients. Significant associations were determined by  
201 a BH-adjusted  $p$ -value  $\leq 0.05$ . Hypergeometric enrichment analysis was used to test for  
202 enrichment between TIL and MRI associated biclusters, where significant enrichment was  
203 defined by a BH-adjusted  $p$ -value  $\leq 0.05$  and an overlap  $> 0$ .

### 204 **Deconvoluting immune cell abundance estimates**

205 The CIBERSORTx deconvolution method was used to estimate immune cell abundance from  
206 bulk gene expression data (30). The MRI and TCGA cohorts were run through CIBERSORTx to  
207 estimate immune cell abundance using the LM22 signature matrix (30). Batch correction and  
208 quantile normalization were disabled, the relative run mode was selected, and 500 permutations  
209 were performed. Results were restricted to include T-cells (CD8+, CD4+ memory resting, and  
210 follicular helper), NK cells (resting and activated), and macrophages/microglia (non-activated,  
211 pro-inflammatory, and anti-inflammatory) to remain consistent with the infiltrating immune cell  
212 types previously identified in GBM tumors (31–34).

### 213 **Associating immune cell estimates to revised bicluster eigengenes**

214 Deconvoluted immune cell fraction estimates were compared to bicluster eigengenes. Pearson  
215 correlations were used to test for associations between deconvoluted immune cell fractions for  
216 the TCGA cohort, because each patient corresponded to a single sample (27). Associations in  
217 the MRI cohort were computed using a MEM with patient ID, tumor purity, and IDH mutational  
218 status as random effects, where patient ID was used to account for repeated samples collected  
219 from the same patient tumor. Significant associations were identified for both the MRI and  
220 TCGA cohorts with a BH-adjusted  $p$ -value  $\leq 0.05$ .

### 221 **Isolating hallmark-specific GOBP terms**

222 For each MRI measurement, the genes from significantly associated revised biclusters were  
223 aggregated into two gene lists: one for positively associated revised biclusters, and a second

224 for negatively associated revised biclusters. Genes were removed if they were members of two  
225 biclusters that had opposite beta value signs with the same MRI measurement (3 genes were  
226 removed in total). Functional enrichment analysis was performed on each gene list using the  
227 enrichr module from the gseapy package (35). Significant GO:BP terms were identified with a  
228 BH-adjusted p-value  $\leq 0.05$  and an overlap ratio of  $\geq 0.1$ . Each GO:BP term was individually  
229 tested for significant semantic similarity with the hallmark(s) of cancer. Hallmark-specific GO:BP  
230 terms were identified with a Jiang-Conrath semantic similarity score  $\geq 0.7$ . For each MRI  
231 measurement, GO:BP terms significantly associated with both the MRI measurement and the  
232 hallmark of cancer ('Self sufficiency in growth signals,' 'Insensitivity to antigrowth signals,' or  
233 'Tissue invasion and metastasis') were isolated for further study.

#### 234 **Associating vessel markup percentage to revised bicluster eigengenes in TCGA**

235 Histologically determined percentages of vessel markup were available for 79 TCGA GBM  
236 tumors (36). A Pearson correlation was performed comparing each bicluster eigengene to  
237 vessel markup percentage. Significant associations were determined by a p-value  $\leq 0.01$ .  
238 Hypergeometric enrichment analysis was used to test for enrichment between vessel and MRI  
239 associated biclusters, where significant enrichment was defined by a BH-adjusted p-value  $\leq$   
240 0.05 and an overlap  $> 0$ .

#### 241 **Calculating percentiles for MRI signal, bicluster expression, and gene expression**

242 MRI measurements (T1+C), revised bicluster eigengenes (PITA-14, TargetsCan-269, and  
243 TargetsCan-541), and transcript levels (CD163) were normalized to scale between 0 and 1  
244 across six MRI samples from patient BNI152 with RNA-seq, tumor purity, and MRI  
245 measurements.



## 246 **Results**

### 247 **Cohorts of HGG tumors**

248 We collected 75 spatially matched biopsies and MRI measurements from 30 HGG patient  
249 tumors (the MRI cohort, **Figure 1A**, **Table S1**). All 75 biopsies were characterized by RNA-seq  
250 and exome-seq to discover transcriptional signatures and tumor purity describing the underlying  
251 composition and molecular changes in each biopsy (13). An average of two and a half image  
252 localized biopsies (one to six biopsies) were collected from CE tumor regions separated by at  
253 least one cm, and average tumor purity, i.e., abundance of tumor cells in the biopsy, was  $63\% \pm$   
254  $20\%$ . We accounted for the repeated sampling from the same tumor and tumor purity by  
255 incorporating them into our statistical tests.

256 The 30 tumors characterized in the MRI cohort cannot capture the full intertumoral  
257 heterogeneity observed between HGG tumors (37). We addressed this gap by incorporating the  
258 TCGA GBM cohort, which extensively profiled the transcriptomes of 422 patient tumors (17, 27).  
259 Previously we constructed the gbmSYGNAL network (17) to discover co-regulated gene  
260 expression signatures, or biclusters, that encapsulate the fundamental biological processes  
261 inherent to GBM tumors (i.e., hallmarks of cancer (18, 19)) (**Figure 1A**). We leverage the  
262 biology encapsulated by the 500 biclusters from gbmSYGNAL to enhance the depth and scope  
263 of our analyses with the MRI cohort. We also used the histological characterization of the TCGA  
264 GBM cohort to validate associations with immune cell infiltration (29) and angiogenesis (36).  
265 The integration of these two complementary cohorts culminates in a powerful platform for  
266 uncovering the HGG tumor biology captured by MRI measurements.

### 267 **Revising gbmSYGNAL biclusters for use with RNA-seq data**

268 Technological differences between RNA-seq (MRI cohort) and microarray (TCGA cohort) are  
269 known to cause discrepancies in gene expression for some genes (38, 39). These  
270 discrepancies led to a lack of positive correlation for a minority of genes within the bicluster  
271 eigengenes of the MRI cohort (**Figure S1A**), which can impact downstream analyses. As a  
272 countermeasure, we devised a series of filters designed to eliminate genes exhibiting  
273 inconsistent expression patterns between platforms. This intervention was designed to ensure  
274 that the bicluster eigengene remains a robust representation of its constituent gene variance  
275 (**Figures S1A-D**). The implementation of the filters yielded a discernible impact: the exclusion  
276 of 1,926 genes (out of 5,194) and 33 biclusters (out of 500) from further analyses (**Table S2**).  
277 For the remaining 467 biclusters there was a reduction in the average number of genes per  
278 bicluster from  $36 \pm 11$  to  $25 \pm 8$ . Importantly, the filters did not significantly alter the number of  
279 biclusters associated with each MRI measurement. The filters improved the results of  
280 downstream functional enrichment analyses (**Figures S1E-S1F**). In summary, the bicluster  
281 revision process removed genes marginally co-expressed in RNA-seq to improve bicluster  
282 coherence and bolstered the signal strength for subsequent functional enrichment analyses.

### 283 **Linking MRI measurements to the hallmarks of cancer**

284 Our primary goal in these studies was to link MRI measurements to the underlying biology of  
285 HGG tumors. We first associated MRI measurements to revised bicluster eigengene expression  
286 using a MEM that corrects for tumor purity, repeated sampling from the same patient tumor, and  
287 IDH mutational status (MRI  $\rightarrow$  bicluster; **Figure 1A**). Our data showed positive associations

288 between all MRI measurements and the expression of at least 12 biclusters (**Figure 1B, Table**  
289 **S3**). Fewer negative associations were discovered that linked MRI measurements to the  
290 expression of biclusters (**Figure 1B, Table S3**).

291 Next, we integrated MRI associated biclusters to hallmarks of cancer using relationships  
292 previously defined in the gbmSYGNAL network (bicluster → hallmark(s) of cancer; **Figure 1A**)  
293 (17). Using the transitive property, we linked MRI measurements to the hallmarks of cancer with  
294 biclusters as the intermediaries (i.e., MRI → bicluster and bicluster → hallmarks of cancer,  
295 therefore MRI → hallmarks of cancer). The biclusters positively associated with MRI were  
296 significantly enriched with biclusters associated with seven hallmarks of cancer (BH-adjusted p-  
297 value < 0.05, **Figure 1C, Table S3**). The biclusters positively associated with T1+C were  
298 significantly enriched with biclusters associated with the immune-related hallmarks ‘Evading  
299 immune detection’ and ‘Tumor promoting inflammation,’ as well as the growth-related hallmarks  
300 ‘Insensitivity to antigrowth signals’ and ‘Self sufficiency in growth signals.’ Biclusters positively  
301 associated with MD and T2W were significantly enriched with ‘Sustained angiogenesis’ and  
302 ‘Tissue invasion & metastasis’ associated biclusters. Biclusters positively associated with T2W  
303 also had a significant enrichment with ‘Evading apoptosis’ hallmark associated biclusters. These  
304 results suggest that the MRI measurements (T1+C, MD, and T2W) might be used as  
305 noninvasive surrogates for seven hallmarks of cancer.

306 We also tested for enrichment between MRI and patient survival associated biclusters (**Figure**  
307 **1D, Table S3**) (17). Biclusters positively associated with T1+C were significantly enriched with  
308 biclusters that predicted shorter patient survival (BH-adjusted p-value =  $4.1 \times 10^{-13}$ ). This  
309 observation is consistent with other studies that have recognized T1+C as a prognostic tool for  
310 HGG (9, 40).

### 311 **T1+C is associated with increased tumor infiltrating lymphocytes**

312 The strongest association we observed in this study linked T1+C to biclusters enriched with the  
313 immune hallmarks of cancer (**Figure 1C**). We validated the association between T1+C and the  
314 immune hallmarks by testing whether the biclusters positively associated with T1+C were  
315 significantly enriched with biclusters associated with histologically-determined TILs in the TCGA  
316 cohort (29). We found that 151 of the 467 revised biclusters were significantly positively  
317 associated with TILs (T-statistic > 0; BH-adjusted p-value ≤ 0.05; **Table S4**). There was a highly  
318 significant enrichment between the TILs and T1+C associated biclusters (overlap = 125; BH-  
319 adjusted p-value =  $1.1 \times 10^{-12}$ ; **Figures 2A-D**). This striking overlap of TIL and T1+C associated  
320 biclusters supports that T1+C could be used as a proxy for tumor immune cell infiltration.

### 321 **T1+C is associated with deconvoluted signatures of immune cell types**

322 We then sought to identify the specific immune cell types infiltrating HGG tumors by examining  
323 associations between biclusters positively linked to T1+C and estimates of immune cell  
324 abundance. We focused our studies on the infiltrating immune cell types observed in HGG  
325 tumors (31–34), which included T-cells (CD8+, CD4+ memory resting, and follicular helper), NK  
326 cells (resting and activated), and macrophages/microglia (non-activated, pro-inflammatory, and  
327 anti-inflammatory). The choice of these cell types was confirmed by the observation that both T-  
328 cells and macrophages/microglia were the most abundant immune cell types in the estimates  
329 for the MRI and TCGA cohorts (**Figures S2A-C**).

330 Next, we tested for associations between the eigengenes from biclusters positively associated  
331 with T1+C and tumor-level estimates for the abundance of each immune subset (**Figures 2E-G;**  
332 **Table S5**). Associations between biclusters positively associated with T1+C and infiltrating  
333 immune cell estimates were considered significant if they replicated across the two  
334 independently collected MRI and TCGA cohorts. No consistent trends were observed for the T-  
335 cells between the two datasets (**Figures 2E & 2H**). We did detect a significant positive  
336 relationship between biclusters positively associated with T1+C and resting NK cells ( $\beta$ -value  
337 and correlation coefficient  $< 0$ ; BH-adjusted p-value  $\leq 0.05$ ; **Figures 2F & 2I**). The most striking  
338 trend we observed was a strong positive relationship between biclusters positively associated  
339 with T1+C and anti-inflammatory macrophages/microglia ( $\beta$ -value and correlation coefficient  $>$   
340  $0$ ; BH-adjusted p-value  $\leq 0.05$ , **Figures 2G & 2J**). The increased infiltration of anti-inflammatory  
341 macrophages/microglia is strongly supported by literature reporting that these cells typically  
342 comprise a substantial fraction of HGG tumor bulk (31–34). A separate study also identified an  
343 increase of bone marrow-derived macrophages/microglia in the CE core of HGG tumors where  
344 T1+C signal is elevated, further supporting the link between T1+C and the presence of  
345 macrophages/microglia (41). Collectively, these findings provide strong evidence that elevated  
346 T1+C levels are linked to an increased presence of anti-inflammatory macrophages/microglia  
347 within the tumor microenvironment.

#### 348 **Leaky vasculature and BBB breakdown leads to influx of contrast agent and immune** 349 **cells**

350 Our analyses showed evidence for a relationship between T1+C signal and tumor immune cell  
351 infiltration, but the underlying biophysical mechanism driving this association still needs to be  
352 explained. The biophysics of T1+C signal is based on the intravenous injection of a GBCA that  
353 is used for both enhancement of vasculature and to visualize HGG tumor burden (14). As HGG  
354 tumors grow, they crush the surrounding tissue and actively secrete enzymes that collectively  
355 lead to a loss in integrity of both the vasculature and BBB at various regions around the tumor  
356 (42–46). This leakiness allows GBCA out of the vasculature and across the BBB, where it  
357 generates a T1+C signal (**Figure 2K**). The genes from T1+C associated biclusters revealed the  
358 mechanisms for the breakdown of vasculature and BBB, and subsequent immune cell  
359 transmigration (**Figure 2K**). The biclusters included the angiogenic factors ANGPT2, FGF2, and  
360 TNF that loosen the walls of vasculature and cell contacts of the BBB in brain  
361 metastases (43, 46). Physical crushing due to tumor growth in a confined space increases  
362 vasculature and BBB breakdown, allowing blood vessel contents to seep into the central  
363 nervous system (CNS) (45). The cell adhesion molecule VCAM1 mediates the adhesion of  
364 immune cells that, during extravasation, can lead to further loss of integrity for vasculature and  
365 the BBB (47, 48). These genes describe the mechanisms that disrupt the vasculature and BBB  
366 and allows GBCA to permeate into the tumor. These results corroborate the well-established  
367 mechanisms that generate the T1+C signal (14).

368 The biclusters positively associated with T1+C also contain genes describing immune cell  
369 infiltration (**Figure 2K**). The VCAM1 pathway members CLDN5, CLDN23, and PLCG2 work  
370 with VCAM1 to signal immune cell transmigration (48, 49). Consistent with our deconvolution  
371 results, CD163 indicates the presence of anti-inflammatory macrophages that have been  
372 polarized by IL10 and IL10RA (50, 51) and TREM2 suggests that microglia are also present

373 (52). Together, these macrophages and microglia constitute glioma-associated  
374 macrophages/microglia (GAMs). Additionally, markers CD2 and CD4 indicate that T-cells join  
375 anti-inflammatory macrophages as part of the invading immune cell population (53, 54). The co-  
376 occurrence of immune infiltration and T1+C signal in our results indicate that peripheral immune  
377 cells are likely crossing into the tumor at the same leaky sites that permit GBCA leakage  
378 (Figure 2K).

379 We observed that genes associated with vasculature and BBB breakdown and the  
380 transmigration of immune cells increase as T1+C signal increases. While the mechanism driving  
381 the elevation of T1+C signal due to vasculature and BBB breakdown is well-documented (42–  
382 46), it's important to note that immune cell transmigration is a downstream consequence of  
383 vasculature and BBB breakdown. Meaning that T1+C does not directly quantify immune cell  
384 infiltration. Consequently, T1+C signal emerges as a valuable surrogate for vasculature and  
385 BBB breakdown and a meaningful albeit indirect indicator of immune cell infiltration within HGG  
386 tumors.

### 387 **T1+C is an indirect proxy for the proliferation of immune cells**

388 Genes that increased when T1+C signal intensified were also associated with proliferation-  
389 related hallmarks of cancer (Figure 1C). The genes from the overlapping biclusters were  
390 strongly enriched with terms related to T-cell proliferation (Figures 3A-3C). This is consistent  
391 with the discovery of CD4<sup>+</sup>, CD8<sup>+</sup>, and follicular helper T-cell sub-population cell estimates in  
392 both the MRI and TCGA cohorts (Figure S2A). Other enriched pathways describe the process  
393 by which the T-cell antigen receptors begin the immune response through the tyrosine kinase  
394 signaling pathway (Figure 3B) to initiate the MAPK cascade and downstream ERK1/ERK2 and  
395 JNK pathways (Figure 3C) that result in proliferation (Figures 3A-3B) (55–57). The activation  
396 and proliferation of T-cells supports our original association between T1+C and infiltrating  
397 immune cells following vasculature and BBB breakdown.

### 398 **T1+C is an indirect proxy for invading immune cell populations**

399 Genes from the biclusters associated with 'Tissue invasion & metastasis' revealed a range of  
400 migration-related processes associated with increasing T1+C signal (Figures 4A-4C). These  
401 functions included immune cell migration, general migration processes, and coagulation  
402 (Figures 4A-4C). The immune-related migration functions split along distinct cell-type  
403 categories (Figure 4A), and the detection of monocytes (which include macrophages) and T-  
404 cell migration replicates our association between T1+C and immune infiltration (Figure 2A-2J).  
405 The migration-specific functions support that these immune cell populations are actively  
406 infiltrating HGGs.

### 407 **Using T1+C as a proxy for immune infiltration within a tumor**

408 The heterogeneity of HGG tumors is a product of the varied anatomical constraints affecting  
409 each part of the tumor (e.g., proximity to vasculature, ventricles, skull, or white matter tracts), as  
410 well as the tumor microenvironment (e.g., overall cellular composition). We collected multiple  
411 samples from a tumor in the MRI cohort which allowed us to directly observe this heterogeneity  
412 at the molecular level through the RNA-seq and indirectly through our new noninvasive MRI  
413 proxies. The six biopsies from the tumor BNI152 are spatially arrayed throughout the CE parts  
414 of the tumor (Figure 5A & B). For each biopsy of patient BNI152's tumor we show the average

415 T1+C signal from the voxels containing the biopsy, the expression of three T1+C associated  
416 bicluster eigengenes, and the expression of a GAM marker gene CD163 (**Figure 5C & D**). The  
417 concordance between T1+C signal and the molecular data demonstrates how T1+C can be  
418 used to spatially map tumor immune cell infiltration (**Figure 5D & E**) that could be used to assist  
419 diagnosis, prognosis, or to assess the effect of immunotherapy on HGG tumors.

#### 420 **Increased MD and T2W are associated with angiogenesis**

421 Increased MD and T2W signal were associated with increased expression of a bicluster linked  
422 to the 'Sustained angiogenesis' cancer hallmark (**Figure 1C**), suggesting that MD and T2W may  
423 be proxies for angiogenesis. The low-strength magnetic field in clinical MRI adeptly captures the  
424 swift flow of fluids commonly present in vasculature. Consequently, both MD, which directly  
425 assesses water movement (3, 58, 59), and T2W, which signifies fluid presence (14), effectively  
426 capture the presence of vasculature, which is typically the origin of angiogenesis. We validated  
427 this relationship using a histologically determined measurement of angiogenesis (percent  
428 angiogenesis) from the TCGA cohort (36) (**Table S6**). First, we determined that 15 revised  
429 biclusters were significantly correlated with histologically determined percent angiogenesis  
430 (correlation coefficient > 0; p-value ≤ 0.01). Expression of four MD and four T2W associated  
431 biclusters were significantly correlated with percent angiogenesis which was more than  
432 expected by chance alone (**Figure 6A-D**; MD enrichment p-value =  $1.2 \times 10^{-4}$ ; and T2W  
433 enrichment p-value =  $4.6 \times 10^{-5}$ ). The relationship between angiogenesis and MD and T2W is  
434 reinforced by the significant overlap with histologically determined angiogenesis.

435 Further examination of the genes in the biclusters associated with MD and T2W revealed a wide  
436 range of biological processes that describe the progression of angiogenesis (**Figure 6E**). KDR,  
437 TIE1, and FLT1 are receptors for signals that initiate angiogenesis. ACVRL1 and ROBO4 are  
438 important receptors for the TGFβ and SLIT pathways, respectively, which promote cell growth  
439 and angiogenesis. PLXDC1 aids in capillary morphogenesis during the sprouting of new  
440 vessels. DLL4 and NOTCH4 regulate the growth of new vessels. PDGFRβ recruits pericytes to  
441 support the walls of new blood vessels. CD34, CDH5, ESAM, and MMRN1 indicate the  
442 presence of endothelial cells lining blood vessel walls. Finally, MYCT1 from the c-MYC pathway  
443 suggests a swift cell division process, ultimately contributing to the supply of cells necessary for  
444 vessel growth. In summary, there is significant histological and enriched angiogenic biology  
445 supporting MD and T2W being useful proxies for angiogenesis in HGG tumors.

#### 446 **MD and T2W are proxies for cellular migration involved in angiogenesis**

447 There are also positive associations linking MD and T2W to the biclusters associated with the  
448 'Tissue invasion & metastasis' cancer hallmark (**Figure 1C**). The genes included in these  
449 'Tissue invasion & metastasis' associated biclusters were enriched with angiogenesis related  
450 migratory processes (**Figure 4D**). The significantly enriched functions include the movement of  
451 endothelial and smooth muscle cells, which are the main cell types in the vasculature (**Figure**  
452 **4D**). Cell migration involved in angiogenic wound healing and sprouting angiogenesis were also  
453 significantly enriched (**Figure 4D**). The formation of angiogenic sprouts requires the  
454 rearrangement and movement of endothelial and smooth muscle cells. These cell migratory  
455 functions are consistent with our findings that MD and T2W are linked to 'Sustained  
456 angiogenesis' and further support their value as proxies for angiogenesis in HGG tumors.

## 457 Discussion

458 In these studies, we demonstrate that the systematic integration of image-localized biopsies  
459 with omics molecular profiles can reveal aspects of HGG tumor biology using noninvasive MRI  
460 measurements. Specifically, we provide evidence connecting T1+C signal to tumor immune  
461 infiltration and MD and T2W signals to angiogenesis. The T1+C MRI measurement directly  
462 captures the breakdown of vasculature and the BBB through the well-established leakage of  
463 contrast dye into the tumor. We also found that T1+C indirectly captures immune cell infiltration  
464 because the breakdown of vasculature and the BBB provides a permissive infiltrative  
465 environment. Moreover, our investigation revealed that MD and T2W effectively capture the  
466 intricate biological process of neovascularization. However, the molecular mechanism(s)  
467 responsible for generating the MRI signal in this context remains an area requiring further  
468 exploration. To fortify these connections between MRI measurements and tumor biology, we  
469 validated our findings using histology and by demonstrating the enrichment of well-established  
470 immune infiltration and angiogenesis pathways in associated gene expression signatures.  
471 Finally, we illustrated how noninvasive MRI can help understand HGG tumor biology spatially  
472 across a tumor, establishing a powerful tool for developing more accurate diagnostic,  
473 prognostic, and treatment efficacy biomarkers for HGG tumors.

474 Increased signal from T1+C indicated the presence of anti-inflammatory GAMs, and resting NK  
475 cells (60). These results are consistent with prior studies showing that HGG tumors are  
476 immunosuppressive (61–63), and this trait is partially attributed to anti-inflammatory GAMs (61–  
477 63). Future studies with spatially matched cohorts that unbiasedly quantify all immune cell types  
478 from HGG tumors directly using single-cell and spatial transcriptomics techniques will be able to  
479 better characterize the relative contributions of all immune cell types in areas of elevated T1+C  
480 signal.

481 Recent studies have demonstrated the potential of MRI biomarkers for angiogenesis by linking  
482 survival benefits from anti-VEGF therapy to the apparent diffusion coefficient (ADC) (64, 65),  
483 which quantifies the same biophysical phenomenon as MD. Patients whose tumors had higher  
484 ADC levels showed nearly double the overall survival when treated with anti-VEGF compared to  
485 those with lower ADC levels. The MRI measurements from the anti-VEGF studies and our MRI  
486 cohort were taken prior to therapy. Our research offers evidence that ADC effectively quantifies  
487 angiogenesis, explaining its utility as a biomarker for predicting the response to anti-angiogenic  
488 therapy. This example showcases how our approach of linking MRI measurements to tumor  
489 biology can be used to inform clinical studies to develop noninvasive biomarkers.

490 T1+C and T2W are commonly used to facilitate many aspects of HGG patient care, including  
491 initial diagnosis, treatment planning, and response assessment after first-line therapy. Our  
492 results enhance the utility of these commonly used MRI measurements by showing they predict  
493 HGG tumor biology. Our discovery that noninvasive MRI measurements are proxies for immune  
494 cell infiltration and angiogenesis lay the groundwork for capturing more HGG tumor biology.  
495 Future studies will incorporate new MRI measurement techniques and test their ability to  
496 capture novel aspects of HGG tumor biology. The long-term goal of this work will allow clinicians  
497 to noninvasively monitor HGG tumor biology, allowing them to improve diagnosis and prognosis,  
498 and respond to treatment in real time, so they can adjust treatment and improve patient survival.

499 **Acknowledgments**

500 This work was supported by NIH-NINDS Award # 1R01NS123038-01, and 1R01NS119650-01.  
501 The authors acknowledge the Glioma Biology Protocol Team for their work in collecting the MRI  
502 cohort and the Cancer Genome Atlas Research Network for the TCGA Pan-Cancer Atlas multi-  
503 omic patient tumor profiles. We also thank Dr. Benjamin Bartelle and Dr. Scott Beeman for  
504 sharing their knowledge of MRI. Figures 2K and 5E were created with BioRender.com.

505 **Author contributions**

506 K.R.S., R.F.B., J.L., N.L.T, L.H., and C.L.P. conceived the project. K.R.S, N.L.T, and L.H.  
507 provided resources through the MRI cohort data. C.L.P. provided resources through the TCGA  
508 cohort data. E.M.L., L.H. and C.L.P curated data from both studies. E.M.L. and C.L.P.  
509 conducted formal analysis, investigations, and validations. E.M.L., L.M., L.W., J.L., and C.L.P.  
510 contributed to visualizations. E.M.L., L.H., and C.L.P. wrote the manuscript. All authors  
511 contributed to the review and editing of the manuscript. N.T.L., L.H., and C.L.P. contributed to  
512 supervision and project administration. K.R.S., R.F.B., J.L., N.L.T, L.H., and C.L.P. contributed  
513 to the funding to support this project.

## 514 References

- 515 1. B. M. Ellingson, M. Bendszus, J. Boxerman, D. Barboriak, B. J. Erickson, M. Smits, S. J. Nelson, E.  
516 Gerstner, B. Alexander, G. Goldmacher, W. Wick, M. Vogelbaum, M. Weller, E. Galanis, J. Kalpathy-  
517 Cramer, L. Shankar, P. Jacobs, W. B. Pope, D. Yang, C. Chung, M. V. Knopp, S. Cha, M. J. van den Bent,  
518 S. Chang, W. K. A. Yung, T. F. Cloughesy, P. Y. Wen, M. R. Gilbert, Jumpstarting Brain Tumor Drug  
519 Development Coalition Imaging Standardization Steering Committee, Consensus recommendations  
520 for a standardized Brain Tumor Imaging Protocol in clinical trials. *Neuro Oncol* **17**, 1188–1198 (2015).
- 521 2. P. Karschnia, J. S. Young, A. Dono, L. Häni, T. Sciortino, F. Bruno, S. T. Juenger, N. Teske, R. A. Morshed,  
522 A. F. Haddad, Y. Zhang, S. Stoecklein, M. Weller, M. A. Vogelbaum, J. Beck, N. Tandon, S. Hervey-  
523 Jumper, A. M. Molinaro, R. Rudà, L. Bello, O. Schnell, Y. Esquenazi, M. I. Ruge, S. J. Grau, M. S. Berger,  
524 S. M. Chang, M. van den Bent, J.-C. Tonn, Prognostic validation of a new classification system for  
525 extent of resection in glioblastoma: A report of the RANO resect group. *Neuro Oncol* **25**, 940–954  
526 (2023).
- 527 3. L. S. Hu, S. Ning, J. M. Eschbacher, L. C. Baxter, N. Gaw, S. Ranjbar, J. Plasencia, A. C. Dueck, S. Peng, K.  
528 A. Smith, P. Nakaji, J. P. Karis, C. C. Quarles, T. Wu, J. C. Loftus, R. B. Jenkins, H. Sicotte, T. M.  
529 Kollmeyer, B. P. O’Neill, W. Elmquist, J. M. Hoxworth, D. Frakes, J. Sarkaria, K. R. Swanson, N. L. Tran,  
530 J. Li, J. R. Mitchell, Radiogenomics to characterize regional genetic heterogeneity in glioblastoma.  
531 *Neuro Oncol* **19**, 128–137 (2017).
- 532 4. B. J. Gill, D. J. Pisapia, H. R. Malone, H. Goldstein, L. Lei, A. Sonabend, J. Yun, J. Samanamud, J. S. Sims,  
533 M. Banu, A. Dovas, A. F. Teich, S. A. Sheth, G. M. McKhann, M. B. Sisti, J. N. Bruce, P. A. Sims, P.  
534 Canoll, MRI-localized biopsies reveal subtype-specific differences in molecular and cellular  
535 composition at the margins of glioblastoma. *Proc Natl Acad Sci U S A* **111**, 12550–12555 (2014).
- 536 5. L. S. Hu, S. Ning, J. M. Eschbacher, N. Gaw, A. C. Dueck, K. A. Smith, P. Nakaji, J. Plasencia, S. Ranjbar,  
537 S. J. Price, N. Tran, J. Loftus, R. Jenkins, B. P. O’Neill, W. Elmquist, L. C. Baxter, F. Gao, D. Frakes, J. P.  
538 Karis, C. Zwart, K. R. Swanson, J. Sarkaria, T. Wu, J. R. Mitchell, J. Li, Multi-Parametric MRI and Texture  
539 Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma. *PLoS One* **10**,  
540 e0141506 (2015).
- 541 6. N. Gaw, A. Hawkins-Daarud, L. S. Hu, H. Yoon, L. Wang, Y. Xu, P. R. Jackson, K. W. Singleton, L. C.  
542 Baxter, J. Eschbacher, A. Gonzales, A. Nespodzany, K. Smith, P. Nakaji, J. R. Mitchell, T. Wu, K. R.  
543 Swanson, J. Li, Integration of machine learning and mechanistic models accurately predicts variation  
544 in cell density of glioblastoma using multiparametric MRI. *Sci Rep* **9**, 10063 (2019).
- 545 7. P. D. Chang, H. R. Malone, S. G. Bowden, D. S. Chow, B. J. A. Gill, T. H. Ung, J. Samanamud, Z. K.  
546 Englander, A. M. Sonabend, S. A. Sheth, G. M. McKhann, M. B. Sisti, L. H. Schwartz, A. Lignelli, J.  
547 Grinband, J. N. Bruce, P. Canoll, A Multiparametric Model for Mapping Cellularity in Glioblastoma  
548 Using Radiographically Localized Biopsies. *AJNR Am J Neuroradiol* **38**, 890–898 (2017).
- 549 8. J. E. Park, H. S. Kim, Y. Jo, R.-E. Yoo, S. H. Choi, S. J. Nam, J. H. Kim, Radiomics prognostication model in  
550 glioblastoma using diffusion- and perfusion-weighted MRI. *Sci Rep* **10**, 4250 (2020).
- 551 9. N. Beig, K. Bera, P. Prasanna, J. Antunes, R. Correa, S. Singh, A. Saeed Bamashmos, M. Ismail, N.  
552 Braman, R. Verma, V. B. Hill, V. Statsevych, M. S. Ahluwalia, V. Varadan, A. Madabhusli, P. Tiwari,



- 553 Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with  
554 Biological Processes in Glioblastoma. *Clin Cancer Res* **26**, 1866–1876 (2020).
- 555 10. H. Akbari, L. Macyszyn, X. Da, M. Bilello, R. L. Wolf, M. Martinez-Lage, G. Biros, M. Alonso-Basanta, D.  
556 M. O'Rourke, C. Davatzikos, Imaging Surrogates of Infiltration Obtained Via Multiparametric Imaging  
557 Pattern Analysis Predict Subsequent Location of Recurrence of Glioblastoma. *Neurosurgery* **78**, 572–  
558 580 (2016).
- 559 11. L. S. Hu, L. Wang, A. Hawkins-Daarud, J. M. Eschbacher, K. W. Singleton, P. R. Jackson, K. Clark-  
560 Swanson, C. P. Sereduk, S. Peng, P. Wang, J. Wang, L. C. Baxter, K. A. Smith, G. L. Mazza, A. M. Stokes,  
561 B. R. Bendok, R. S. Zimmerman, C. Krishna, A. B. Porter, M. M. Mrugala, J. M. Hoxworth, T. Wu, N. L.  
562 Tran, K. R. Swanson, J. Li, Uncertainty quantification in the radiogenomics modeling of EGFR  
563 amplification in glioblastoma. *Sci Rep* **11**, 3932 (2021).
- 564 12. H. R. Cho, H. Jeon, C.-K. Park, S.-H. Park, S. H. Choi, Radiogenomics Profiling for Glioblastoma-related  
565 Immune Cells Reveals CD49d Expression Correlation with MRI parameters and Prognosis. *Sci Rep* **8**,  
566 16022 (2018).
- 567 13. L. S. Hu, F. D'Angelo, T. M. Weiskittel, F. P. Caruso, S. P. Fortin Ensign, M. R. Blomquist, M. J. Flick, L.  
568 Wang, C. P. Sereduk, K. Meng-Lin, G. De Leon, A. Nespodzany, J. C. Urcuyo, A. C. Gonzales, L. Curtin,  
569 E. M. Lewis, K. W. Singleton, T. Dondlinger, A. Anil, N. B. Semmineh, T. Noviello, R. A. Patel, P. Wang,  
570 J. Wang, J. M. Eschbacher, A. Hawkins-Daarud, P. R. Jackson, I. S. Grunfeld, C. Elrod, G. L. Mazza, S. C.  
571 McGee, L. Paulson, K. Clark-Swanson, Y. Lassiter-Morris, K. A. Smith, P. Nakaji, B. R. Bendok, R. S.  
572 Zimmerman, C. Krishna, D. P. Patra, N. P. Patel, M. Lyons, M. Neal, K. Donev, M. M. Mrugala, A. B.  
573 Porter, S. C. Beeman, T. R. Jensen, K. M. Schmainda, Y. Zhou, L. C. Baxter, C. L. Plaisier, J. Li, H. Li, A.  
574 Lasorella, C. C. Quarles, K. R. Swanson, M. Ceccarelli, A. Iavarone, N. L. Tran, Integrated molecular and  
575 multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures. *Nat*  
576 *Commun* **14**, 6066 (2023).
- 577 14. L. S. Hu, A. Hawkins-Daarud, L. Wang, J. Li, K. R. Swanson, Imaging of intratumoral heterogeneity in  
578 high-grade glioma. *Cancer Lett* **477**, 97–106 (2020).
- 579 15. L. A. Mohsen, V. Shi, R. Jena, J. H. Gillard, S. J. Price, Diffusion tensor invasive phenotypes can predict  
580 progression-free survival in glioblastomas. *Br J Neurosurg* **27**, 436–441 (2013).
- 581 16. R. F. Barajas, J. J. Phillips, R. Parvataneni, A. Molinaro, E. Essock-Burns, G. Bourne, A. T. Parsa, M. K.  
582 Aghi, M. W. McDermott, M. S. Berger, S. Cha, S. M. Chang, S. J. Nelson, Regional variation in  
583 histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with  
584 anatomic and physiologic MR Imaging. *Neuro Oncol* **14**, 942–954 (2012).
- 585 17. C. L. Plaisier, S. O'Brien, B. Bernard, S. Reynolds, Z. Simon, C. M. Toledo, Y. Ding, D. J. Reiss, P. J.  
586 Paddison, N. S. Baliga, Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using  
587 Systems Genetics Network Analysis. *Cell Syst* **3**, 172–186 (2016).
- 588 18. D. Hanahan, R. A. Weinberg, The hallmarks of cancer. *Cell* **100**, 57–70 (2000).
- 589 19. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: the next generation. *Cell* **144**, 646–674 (2011).

- 590 20. C. L. Plaisier, M. Pan, N. S. Baliga, A miRNA-regulatory network explains how dysregulated miRNAs  
591 perturb oncogenic processes across diverse cancers. *Genome Res.* **22**, 2302–2314 (2012).
- 592 21. B. M. Alexander, T. F. Cloughesy, Adult Glioblastoma. *J Clin Oncol* **35**, 2402–2409 (2017).
- 593 22. M. Jenkinson, C. F. Beckmann, T. E. J. Behrens, M. W. Woolrich, S. M. Smith, FSL. *Neuroimage* **62**,  
594 782–790 (2012).
- 595 23. S. J. Price, R. Jena, N. G. Burnet, P. J. Hutchinson, A. F. Dean, A. Peña, J. D. Pickard, T. A. Carpenter, J.  
596 H. Gillard, Improved delineation of glioma margins and regions of infiltration with the use of diffusion  
597 tensor imaging: an image-guided biopsy study. *AJNR Am J Neuroradiol* **27**, 1969–1974 (2006).
- 598 24. M. McCormick, X. Liu, J. Jomier, C. Marion, L. Ibanez, ITK: enabling reproducible research and open  
599 science. *Front Neuroinform* **8**, 13 (2014).
- 600 25. F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer,  
601 R. Weiss, V. Dubourg, J. Vanderplas, A. Passos, D. Cournapeau, M. Brucher, M. Perrot, É. Duchesnay,  
602 Scikit-learn: Machine Learning in Python. *Journal of Machine Learning Research* **12**, 2825–2830  
603 (2011).
- 604 26. S. Seabold, J. Perktold, in *Proceedings of the 9th Python in Science Conference*, S. van der Walt, J.  
605 Millman, Eds. (2010), pp. 92–96.
- 606 27. V. Thorsson, D. L. Gibbs, S. D. Brown, D. Wolf, D. S. Bortone, T.-H. Ou Yang, E. Porta-Pardo, G. F. Gao,  
607 C. L. Plaisier, J. A. Eddy, E. Ziv, A. C. Culhane, E. O. Paull, I. K. A. Sivakumar, A. J. Gentles, R. Malhotra,  
608 F. Farshidfar, A. Colaprico, J. S. Parker, L. E. Mose, N. S. Vo, J. Liu, Y. Liu, J. Rader, V. Dhankani, S. M.  
609 Reynolds, R. Bowlby, A. Califano, A. D. Cherniack, D. Anastassiou, D. Bedognetti, Y. Mokrab, A. M.  
610 Newman, A. Rao, K. Chen, A. Krasnitz, H. Hu, T. M. Malta, H. Noushmehr, C. S. Peadamallu, S. Bullman,  
611 A. I. Ojesina, A. Lamb, W. Zhou, H. Shen, T. K. Choueiri, J. N. Weinstein, J. Guinney, J. Saltz, R. A. Holt,  
612 C. S. Rabkin, Cancer Genome Atlas Research Network, A. J. Lazar, J. S. Serody, E. G. Demicco, M. L.  
613 Disis, B. G. Vincent, I. Shmulevich, The Immune Landscape of Cancer. *Immunity* **48**, 812-830.e14  
614 (2018).
- 615 28. J. Liu, T. Lichtenberg, K. A. Hoadley, L. M. Poisson, A. J. Lazar, A. D. Cherniack, A. J. Kovatich, C. C.  
616 Benz, D. A. Levine, A. V. Lee, L. Omberg, D. M. Wolf, C. D. Shriver, V. Thorsson, Cancer Genome Atlas  
617 Research Network, H. Hu, An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-  
618 Quality Survival Outcome Analytics. *Cell* **173**, 400-416.e11 (2018).
- 619 29. W. C. Rutledge, J. Kong, J. Gao, D. A. Gutman, L. A. D. Cooper, C. Appin, Y. Park, L. Scarpace, T.  
620 Mikkelsen, M. L. Cohen, K. D. Aldape, R. E. McLendon, N. L. Lehman, C. R. Miller, M. J. Schniederjan,  
621 C. W. Brennan, J. H. Saltz, C. S. Moreno, D. J. Brat, Tumor-infiltrating lymphocytes in glioblastoma are  
622 associated with specific genomic alterations and related to transcriptional class. *Clin. Cancer Res.* **19**,  
623 4951–4960 (2013).
- 624 30. A. M. Newman, C. B. Steen, C. L. Liu, A. J. Gentles, A. A. Chaudhuri, F. Scherer, M. S. Khodadoust, M.  
625 S. Esfahani, B. A. Luca, D. Steiner, M. Diehn, A. A. Alizadeh, Determining cell type abundance and  
626 expression from bulk tissues with digital cytometry. *Nat Biotechnol* **37**, 773–782 (2019).

- 627 31. N. Abdelfattah, P. Kumar, C. Wang, J.-S. Leu, W. F. Flynn, R. Gao, D. S. Baskin, K. Pichumani, O. B.  
628 Ijare, S. L. Wood, S. Z. Powell, D. L. Haviland, B. C. Parker Kerrigan, F. F. Lang, S. S. Prabhu, K. M.  
629 Huntoon, W. Jiang, B. Y. S. Kim, J. George, K. Yun, Single-cell analysis of human glioma and immune  
630 cells identifies S100A4 as an immunotherapy target. *Nat Commun* **13**, 767 (2022).
- 631 32. E. Friebel, K. Kapolou, S. Unger, N. G. Núñez, S. Utz, E. J. Rushing, L. Regli, M. Weller, M. Greter, S.  
632 Tugues, M. C. Neidert, B. Becher, Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific  
633 Instruction of Tissue-Invading Leukocytes. *Cell* **181**, 1626-1642.e20 (2020).
- 634 33. F. Klemm, R. R. Maas, R. L. Bowman, M. Kornete, K. Soukup, S. Nassiri, J.-P. Brouland, C. A. Iacobuzio-  
635 Donahue, C. Brennan, V. Tabar, P. H. Gutin, R. T. Daniel, M. E. Hegi, J. A. Joyce, Interrogation of the  
636 Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells.  
637 *Cell* **181**, 1643-1660.e17 (2020).
- 638 34. C. Neftel, J. Laffy, M. G. Filbin, T. Hara, M. E. Shore, G. J. Rahme, A. R. Richman, D. Silverbush, M. L.  
639 Shaw, C. M. Hebert, J. Dewitt, S. Gritsch, E. M. Perez, L. N. Gonzalez Castro, X. Lan, N. Druck, C.  
640 Rodman, D. Dionne, A. Kaplan, M. S. Bertalan, J. Small, K. Pelton, S. Becker, D. Bonal, Q.-D. Nguyen, R.  
641 L. Servis, J. M. Fung, R. Mylvaganam, L. Mayr, J. Gojo, C. Haberler, R. Geyeregger, T. Czech, I. Slavc, B.  
642 V. Nahed, W. T. Curry, B. S. Carter, H. Wakimoto, P. K. Brastianos, T. T. Batchelor, A. Stemmer-  
643 Rachamimov, M. Martinez-Lage, M. P. Frosch, I. Stamenkovic, N. Riggi, E. Rheinbay, M. Monje, O.  
644 Rozenblatt-Rosen, D. P. Cahill, A. P. Patel, T. Hunter, I. M. Verma, K. L. Ligon, D. N. Louis, A. Regev, B.  
645 E. Bernstein, I. Tirosh, M. L. Suvà, An Integrative Model of Cellular States, Plasticity, and Genetics for  
646 Glioblastoma. *Cell* **178**, 835-849.e21 (2019).
- 647 35. M. V. Kuleshov, M. R. Jones, A. D. Rouillard, N. F. Fernandez, Q. Duan, Z. Wang, S. Koplev, S. L.  
648 Jenkins, K. M. Jagodnik, A. Lachmann, M. G. McDermott, C. D. Monteiro, G. W. Gundersen, A.  
649 Ma'ayan, Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic  
650 Acids Res* **44**, W90-97 (2016).
- 651 36. L. A. D. Cooper, D. A. Gutman, C. Chisolm, C. Appin, J. Kong, Y. Rong, T. Kurc, E. G. Van Meir, J. H.  
652 Saltz, C. S. Moreno, D. J. Brat, The tumor microenvironment strongly impacts master transcriptional  
653 regulators and gene expression class of glioblastoma. *Am J Pathol* **180**, 2108–2119 (2012).
- 654 37. C. W. Brennan, R. G. W. Verhaak, A. McKenna, B. Campos, H. Noushmehr, S. R. Salama, S. Zheng, D.  
655 Chakravarty, J. Z. Sanborn, S. H. Berman, R. Beroukhi, B. Bernard, C.-J. Wu, G. Genovese, I.  
656 Shmulevich, J. Barnholtz-Sloan, L. Zou, R. Vegesna, S. A. Shukla, G. Ciriello, W. K. Yung, W. Zhang, C.  
657 Sougnez, T. Mikkelsen, K. Aldape, D. D. Bigner, E. G. Van Meir, M. Prados, A. Sloan, K. L. Black, J.  
658 Eschbacher, G. Finocchiaro, W. Friedman, D. W. Andrews, A. Guha, M. Iacocca, B. P. O'Neill, G. Foltz,  
659 J. Myers, D. J. Weisenberger, R. Penny, R. Kucherlapati, C. M. Perou, D. N. Hayes, R. Gibbs, M. Marra,  
660 G. B. Mills, E. Lander, P. Spellman, R. Wilson, C. Sander, J. Weinstein, M. Meyerson, S. Gabriel, P. W.  
661 Laird, D. Haussler, G. Getz, L. Chin, TCGA Research Network, The somatic genomic landscape of  
662 glioblastoma. *Cell* **155**, 462–477 (2013).
- 663 38. S. Zhao, W.-P. Fung-Leung, A. Bittner, K. Ngo, X. Liu, Comparison of RNA-Seq and microarray in  
664 transcriptome profiling of activated T cells. *PLoS One* **9**, e78644 (2014).
- 665 39. W. Zhang, Y. Yu, F. Hertwig, J. Thierry-Mieg, W. Zhang, D. Thierry-Mieg, J. Wang, C. Furlanello, V.  
666 Devanarayan, J. Cheng, Y. Deng, B. Hero, H. Hong, M. Jia, L. Li, S. M. Lin, Y. Nikolsky, A. Oberthuer, T.  
667 Qing, Z. Su, R. Volland, C. Wang, M. D. Wang, J. Ai, D. Albanese, S. Asgharzadeh, S. Avigad, W. Bao, M.

- 668 Bessarabova, M. H. Brilliant, B. Brors, M. Chierici, T.-M. Chu, J. Zhang, R. G. Grundy, M. M. He, S.  
669 Hebbring, H. L. Kaufman, S. Lababidi, L. J. Lancashire, Y. Li, X. X. Lu, H. Luo, X. Ma, B. Ning, R. Noguera,  
670 M. Peifer, J. H. Phan, F. Roels, C. Rosswog, S. Shao, J. Shen, J. Theissen, G. P. Tonini, J. Vandesompele,  
671 P.-Y. Wu, W. Xiao, J. Xu, W. Xu, J. Xuan, Y. Yang, Z. Ye, Z. Dong, K. K. Zhang, Y. Yin, C. Zhao, Y. Zheng, R.  
672 D. Wolfinger, T. Shi, L. H. Malkas, F. Berthold, J. Wang, W. Tong, L. Shi, Z. Peng, M. Fischer,  
673 Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. *Genome Biol*  
674 **16**, 133 (2015).
- 675 40. N. Beig, J. Patel, P. Prasanna, V. Hill, A. Gupta, R. Correa, K. Bera, S. Singh, S. Partovi, V. Varadan, M.  
676 Ahluwalia, A. Madabhushi, P. Tiwari, Radiogenomic analysis of hypoxia pathway is predictive of  
677 overall survival in Glioblastoma. *Sci Rep* **8**, 7 (2018).
- 678 41. A. Salvalaggio, E. Silvestri, G. Sansone, L. Pinton, S. Magri, C. Briani, M. Anglani, G. Lombardi, V.  
679 Zagonel, A. Della Puppa, S. Mandruzzato, M. Corbetta, A. Bertoldo, Magnetic Resonance Imaging  
680 Correlates of Immune Microenvironment in Glioblastoma. *Front Oncol* **12**, 823812 (2022).
- 681 42. G. P. Cribaro, E. Saavedra-López, L. Romarate, I. Mitxitorena, L. R. Díaz, P. V. Casanova, M. Roig-  
682 Martínez, J. M. Gallego, A. Perez-Vallés, C. Barcia, Three-dimensional vascular microenvironment  
683 landscape in human glioblastoma. *Acta Neuropathol Commun* **9**, 24 (2021).
- 684 43. B. K. Ahir, H. H. Engelhard, S. S. Lakka, Tumor Development and Angiogenesis in Adult Brain Tumor:  
685 Glioblastoma. *Mol Neurobiol* **57**, 2461–2478 (2020).
- 686 44. J. N. Sarkaria, L. S. Hu, I. F. Parney, D. H. Pafundi, D. H. Brinkmann, N. N. Laack, C. Giannini, T. C.  
687 Burns, S. H. Kizilbash, J. K. Laramy, K. R. Swanson, T. J. Kaufmann, P. D. Brown, N. Y. R. Agar, E.  
688 Galanis, J. C. Buckner, W. F. Elmquist, Is the blood-brain barrier really disrupted in all glioblastomas?  
689 A critical assessment of existing clinical data. *Neuro Oncol* **20**, 184–191 (2018).
- 690 45. D. Hambardzumyan, G. Bergers, Glioblastoma: Defining Tumor Niches. *Trends Cancer* **1**, 252–265  
691 (2015).
- 692 46. J. J. Connell, G. Chatain, B. Cornelissen, K. A. Vallis, A. Hamilton, L. Seymour, D. C. Anthony, N. R.  
693 Sibson, Selective permeabilization of the blood-brain barrier at sites of metastasis. *J Natl Cancer Inst*  
694 **105**, 1634–1643 (2013).
- 695 47. A. Haarmann, E. Nowak, A. Deiß, S. van der Pol, C.-M. Monoranu, G. Kooij, N. Müller, P. van der Valk,  
696 G. Stoll, H. E. de Vries, F. Berberich-Siebelt, M. Buttman, Soluble VCAM-1 impairs human brain  
697 endothelial barrier integrity via integrin  $\alpha$ -4-transduced outside-in signalling. *Acta Neuropathol* **129**,  
698 639–652 (2015).
- 699 48. J. M. Cook-Mills, M. E. Marchese, H. Abdala-Valencia, Vascular cell adhesion molecule-1 expression  
700 and signaling during disease: regulation by reactive oxygen species and antioxidants. *Antioxid Redox*  
701 *Signal* **15**, 1607–1638 (2011).
- 702 49. F. Belinky, N. Nativ, G. Stelzer, S. Zimmerman, T. Iny Stein, M. Safran, D. Lancet, PathCards: multi-  
703 source consolidation of human biological pathways. *Database (Oxford)* **2015**, bav006 (2015).

- 704 50. H. Li, D. Wang, B. Yi, H. Cai, Z. Xi, X. Lou, Z. Li, Comprehensive Analysis of CD163 as a Prognostic  
705 Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme. *Biomed Res Int* **2021**,  
706 8357585 (2021).
- 707 51. A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, M. Locati, The chemokine system in diverse  
708 forms of macrophage activation and polarization. *Trends Immunol* **25**, 677–686 (2004).
- 709 52. N. Geribaldi-Doldán, C. Fernández-Ponce, R. N. Quiroz, I. Sánchez-Gomar, L. G. Escorcía, E. P.  
710 Velásquez, E. N. Quiroz, The Role of Microglia in Glioblastoma. *Front Oncol* **10**, 603495 (2020).
- 711 53. C. Binder, F. Cvetkovski, F. Sellberg, S. Berg, H. Paternina Visbal, D. H. Sachs, E. Berglund, D.  
712 Berglund, CD2 Immunobiology. *Front Immunol* **11**, 1090 (2020).
- 713 54. V. Golubovskaya, L. Wu, Different Subsets of T Cells, Memory, Effector Functions, and CAR-T  
714 Immunotherapy. *Cancers (Basel)* **8**, 36 (2016).
- 715 55. D. Cantrell, T cell antigen receptor signal transduction pathways. *Annu Rev Immunol* **14**, 259–274  
716 (1996).
- 717 56. C. A. J. Jr, P. Travers, M. Walport, M. J. Shlomchik, C. A. J. Jr, P. Travers, M. Walport, M. J. Shlomchik,  
718 *Immunobiology* (Garland Science, ed. 5th, 2001).
- 719 57. K. Adachi, M. M. Davis, T-cell receptor ligation induces distinct signaling pathways in naive vs.  
720 antigen-experienced T cells. *Proc Natl Acad Sci U S A* **108**, 1549–1554 (2011).
- 721 58. L. Tang, X. J. Zhou, Diffusion MRI of cancer: From low to high b-values. *J Magn Reson Imaging* **49**,  
722 23–40 (2019).
- 723 59. C. Han, L. Zhao, S. Zhong, X. Wu, J. Guo, X. Zhuang, H. Han, A comparison of high b-value vs standard  
724 b-value diffusion-weighted magnetic resonance imaging at 3.0T for medulloblastomas. *Br J Radiol*  
725 **88**, 20150220 (2015).
- 726 60. C. N. Kersch, L. L. Muldoon, C. J. Claunch, R. Fu, D. Schwartz, S. Cha, J. Starkey, E. A. Neuwelt, R. F.  
727 Barajas, Multiparametric magnetic resonance imaging discerns glioblastoma immune  
728 microenvironmental heterogeneity. *Neuroradiol J*, 19714009231163560 (2023).
- 729 61. B. T. Himes, P. A. Geiger, K. Ayasoufi, A. G. Bhargav, D. A. Brown, I. F. Parney, Immunosuppression in  
730 Glioblastoma: Current Understanding and Therapeutic Implications. *Front Oncol* **11**, 770561 (2021).
- 731 62. Z. Zhu, H. Zhang, B. Chen, X. Liu, S. Zhang, Z. Zong, M. Gao, PD-L1-Mediated Immunosuppression in  
732 Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated  
733 Macrophages. *Front Immunol* **11**, 588552 (2020).
- 734 63. E. K. Nduom, M. Weller, A. B. Heimberger, Immunosuppressive mechanisms in glioblastoma. *Neuro*  
735 *Oncol* **17 Suppl 7**, vii9–vii14 (2015).
- 736 64. K. S. Patel, R. G. Everson, J. Yao, C. Raymond, J. Goldman, J. Schlossman, J. Tsung, C. Tan, W. B. Pope,  
737 M. S. Ji, N. T. Nguyen, A. Lai, P. L. Nghiemphu, L. M. Liau, T. F. Cloughesy, B. M. Ellingson, Diffusion

- 738       Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or  
739       Surgery in Recurrent Glioblastoma With Large Tumor Burden. *Neurosurgery* **87**, 931–938 (2020).
- 740   65. B. M. Ellingson, E. R. Gerstner, M. Smits, R. Y. Huang, R. Colen, L. E. Abrey, D. T. Aftab, G. M. Schwab,  
741       C. Hessel, R. J. Harris, A. Chakhoyan, R. Gahrman, W. B. Pope, K. Leu, C. Raymond, D. C. Woodworth,  
742       J. de Groot, P. Y. Wen, T. T. Batchelor, M. J. van den Bent, T. F. Cloughesy, Diffusion MRI Phenotypes  
743       Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging  
744       Evidence from Phase II Trials. *Clin Cancer Res* **23**, 5745–5756 (2017).
- 745

## 746 **Figure legends**

747 **Figure 1.** Associating MRI measurements with HGG tumor biology. **(A)** Biclusters from the  
748 gbmSYGNAL network were refined using RNA-seq data from the MRI cohort and were then  
749 used to associate MRI measurements and HGG tumor biology. **(B)** Number of biclusters  
750 associated with MRI measurements separated by positive and negative relationships with MRI  
751 signal. The Total column in yellow denotes number of biclusters associated with any MRI  
752 measurement, regardless of sign. **(C)** Number of biclusters associated with MRI and hallmarks  
753 of cancer separated by hallmark. Significant enrichment of MRI and hallmarks of cancer  
754 associated biclusters are denoted by a cyan outline. **(D)** Number of biclusters associated with  
755 MRI and patient survival separated by relationship with prognosis. Significant enrichment  
756 between MRI and patient survival associated biclusters are denoted by an orange outline.

757 **Figure 2.** Validating the association of T1+C with infiltrating immune cells. Histologically  
758 determined TIL levels were tested for association with bicluster eigengene expression using a  
759 T-test for biclusters positively **(A)** and negatively **(B)** associated with MRI measurements.  
760 Significant associations with a bicluster are shown with darker red **(A)** or green **(B)** colors.  
761 Hypergeometric enrichment between TIL and positively **(C)** and negatively **(D)** MRI associated  
762 biclusters. “Pos. stat.” indicates a positive T-statistic and “Neg. stat.” indicates a negative T-  
763 statistic. Boxes with a dashed line indicate zero overlapping biclusters (z.o.). Associations  
764 between infiltrating immune cell estimates and T1+C bicluster eigengenes for T-cells **(E)**, NK  
765 cells **(F)**, and macrophages/microglia **(G)** using a MEM for the MRI cohort (left y-axis) and using  
766 correlation for the TCGA cohort (right y-axis). Significantly associated biclusters from the MRI  
767 cohort are denoted by darker blue and from the TCGA cohort are denoted by darker red.  
768 Hypergeometric enrichment between biclusters positively associated with T1+C and biclusters  
769 associated with T-cells **(H)**, NK cells **(I)**, and macrophages/microglia **(J)**. “Pos. assoc.” indicates  
770 a positive association and “Neg. assoc.” indicates an inverse association. “Pro-inflamm.”  
771 indicates pro-inflammatory macrophages/microglia and “Anti-inflamm.” indicates anti-  
772 inflammatory macrophages/microglia. **(K)** Schematic of vasculature and BBB breakdown  
773 characteristic of HGG tumors. Green text represents the genes and functions included in T1+C  
774 biclusters.

775 **Figure 3.** Proliferation-related biological processes enriched in imaging associated bicluster  
776 genes. Grouped by immune **(A)**, growth **(B)**, signaling **(C)**, and vessel **(D)** related proliferation  
777 processes.


778 **Figure 4.** Invasion-related biological processes enriched in imaging associated bicluster genes.  
779 Grouped by immune **(A)**, general **(B)**, blood **(C)**, and vessel **(D)** related migration processes.

780 **Figure 5.** MRI captures immune infiltration across tumor biopsies. **(A)** Biopsy locations (red)  
781 within the tumor (yellow). **(B)** Z-coordinate of the slice of the MRI capture for each sample. **(C)**  
782 T1+C MRI image slice showing the biopsy location of each sample. **(D)** Percentiles of MRI  
783 signal, bicluster expression, and gene expression related to immune infiltration for each sample.  
784 **(E)** Percentiles of MRI signal, bicluster expression, and gene expression related to immune  
785 infiltration for each sample overlaid onto tumor spatial locations.

786 **Figure 6.** MD and T2W are associated with angiogenesis. Correlation between angiogenesis  
787 percentage and biclusters positively (**A**) and negatively (**B**) associated with MRI measurements.  
788 Hypergeometric enrichment between biclusters associated with angiogenesis percentage and  
789 biclusters positively (**C**) and negatively (**D**) associated with each MRI measurement. “Pos. coef.”  
790 indicates a positive correlation and “Neg. coef.” indicates an inverse correlation. Boxes with a  
791 dashed line indicate zero overlapping biclusters (z.o.). (**E**) MD and T2W biclusters contain  
792 genes (purple) from sprouting angiogenesis.



793 **Figures**  
794 **Figure 1.**



**B**

□ = Sig. hallmark enrichment  
□ = Sig. survival enrichment

**C**

**Biclusters associated with MRI & hallmark of cancer**

	Total	Positive mpMRI associations				Negative mpMRI associations			
		FA	MD	T1+C	T2W	FA	MD	T1+C	T2W
<b>MRI-associated</b>	274	43	16	191	12	1	17	17	58
Sustained angiogenesis	3	0	1	0	1	0	1	0	0
Insensitivity to antgrowth signals	16	2	0	10	0	0	0	1	2
Self sufficiency in growth signals	17	2	0	11	0	0	0	1	2
Evading immune detection	58	2	0	58	0	0	0	0	4
Tumor promoting inflammation	58	2	0	58	0	0	0	0	4
Tissue invasion & metastasis	12	1	5	3	6	1	0	0	1
Evading apoptosis	3	0	0	0	1	1	0	0	0
Reprogramming energy metabolism	1	0	0	0	0	0	0	0	0
Genome instability & mutation	7	0	0	0	0	0	0	0	0
Unlimited replicative potential	0	0	0	0	0	0	0	0	0
<b>Associated to worse prognosis</b>	198	17	2	104	2	0	1	1	20
<b>Associated to better prognosis</b>	5	0	0	0	0	0	0	0	0


**D**

Number of biclusters

60  
40  
20  
10  
5  
0

795


796 **Figure 2.**




797

798

799 **Figure 3.**




801 **Figure 4.**




802

803 **Figure 5.**



804


805 **Figure 6.**



806

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

## Analysis in MRI cohort



**B**


□ = Sig. hallmark enrichment  
 □ = Sig. survival enrichment

**C**


Biclusters associated with MRI & hallmark of cancer

	Total	Positive mpMRI associations				Negative mpMRI associations			
		FA	MD	T1+C	T2W	FA	MD	T1+C	T2W
MRI-associated	274	43	16	191	12	1	17	17	58
Sustained angiogenesis	3	0	1	0	1	0	1	0	0
Insensitivity to antigrowth signals	16	2	0	10	0	0	1	2	
Self sufficiency in growth signals	17	2	0	11	0	0	1	2	
Evading immune detection	58	2	0	58	0	0	0	4	
Tumor promoting inflammation	58	2	0	58	0	0	0	4	
Tissue invasion & metastasis	12	1	5	3	6	1	0	0	1
Evading apoptosis	3	0	0	0	1	1	0	0	0
Reprogramming energy metabolism	1	0	0	0	0	0	0	0	0
Genome instability & mutation	7	0	0	0	0	0	0	0	0
Limitless replicative potential	0	0	0	0	0	0	0	0	0
Associated to worse prognosis	198	17	2	104	2	0	1	1	20
Associated to better prognosis	5	0	0	0	0	0	0	0	0

**D**




It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).







It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

